439 related articles for article (PubMed ID: 20070992)
41. Telmisartan exerts sustained blood pressure control and reduces blood pressure variability in metabolic syndrome by inhibiting sympathetic activity.
Sueta D; Koibuchi N; Hasegawa Y; Toyama K; Uekawa K; Katayama T; Ma M; Nakagawa T; Ogawa H; Kim-Mitsuyama S
Am J Hypertens; 2014 Dec; 27(12):1464-71. PubMed ID: 24871627
[TBL] [Abstract][Full Text] [Related]
42. Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system.
Tuck ML
Curr Hypertens Rep; 2005 Aug; 7(4):240-3. PubMed ID: 16061040
[TBL] [Abstract][Full Text] [Related]
43. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion.
Washida K; Ihara M; Nishio K; Fujita Y; Maki T; Yamada M; Takahashi J; Wu X; Kihara T; Ito H; Tomimoto H; Takahashi R
Stroke; 2010 Aug; 41(8):1798-806. PubMed ID: 20595663
[TBL] [Abstract][Full Text] [Related]
44. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity.
Mori Y; Itoh Y; Tajima N
Am J Hypertens; 2007 Apr; 20(4):431-6. PubMed ID: 17386352
[TBL] [Abstract][Full Text] [Related]
45. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome.
Ichikawa Y
Intern Med; 2007; 46(17):1331-6. PubMed ID: 17827829
[TBL] [Abstract][Full Text] [Related]
46. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Benson SC; Pershadsingh HA; Ho CI; Chittiboyina A; Desai P; Pravenec M; Qi N; Wang J; Avery MA; Kurtz TW
Hypertension; 2004 May; 43(5):993-1002. PubMed ID: 15007034
[TBL] [Abstract][Full Text] [Related]
47. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.
Sanchez RA; Masnatta LD; Pesiney C; Fischer P; Ramirez AJ
J Hypertens; 2008 Dec; 26(12):2393-8. PubMed ID: 19008718
[TBL] [Abstract][Full Text] [Related]
48. Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action.
Zhao ZQ; Luo R; Li LY; Tian FS; Zheng XL; Xiong HL; Sun LT
Can J Diabetes; 2013 Jun; 37(3):156-68. PubMed ID: 24070838
[TBL] [Abstract][Full Text] [Related]
49. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.
Yamada S; Ano N; Toda K; Kitaoka A; Shiono K; Inoue G; Atsuda K; Irie J
Hypertens Res; 2008 Apr; 31(4):601-6. PubMed ID: 18633170
[TBL] [Abstract][Full Text] [Related]
50. Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia.
Kasahara Y; Taguchi A; Uno H; Nakano A; Nakagomi T; Hirose H; Stern DM; Matsuyama T
Brain Res; 2010 Jun; 1340():70-80. PubMed ID: 20388500
[TBL] [Abstract][Full Text] [Related]
51. Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties.
Zanchi A; Dulloo AG; Perregaux C; Montani JP; Burnier M
Am J Physiol Endocrinol Metab; 2007 Jul; 293(1):E91-5. PubMed ID: 17374699
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?
Benson SC; Iguchi R; Ho CI; Yamamoto K; Kurtz TW
J Hypertens; 2008 May; 26(5):973-80. PubMed ID: 18398340
[TBL] [Abstract][Full Text] [Related]
53. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
[TBL] [Abstract][Full Text] [Related]
54. Telmisartan protects against cognitive decline via up-regulation of brain-derived neurotrophic factor/tropomyosin-related kinase B in hippocampus of hypertensive rats.
Kishi T; Hirooka Y; Sunagawa K
J Cardiol; 2012 Dec; 60(6):489-94. PubMed ID: 22948091
[TBL] [Abstract][Full Text] [Related]
55. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
Mori Y; Tanaka T; Matsuura K; Yokoyama J; Utsunomiya K
Adv Ther; 2011 Aug; 28(8):698-706. PubMed ID: 21744143
[TBL] [Abstract][Full Text] [Related]
56. Effect of telmisartan on the expression of cardiac adiponectin and its receptor 1 in type 2 diabetic rats.
Guo Z; Zheng C; Qin Z; Wei P
J Pharm Pharmacol; 2011 Jan; 63(1):87-94. PubMed ID: 21155820
[TBL] [Abstract][Full Text] [Related]
57. Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats.
Ma L; Ji JL; Ji H; Yu X; Ding LJ; Liu K; Li YQ
Bone; 2010 Jul; 47(1):5-11. PubMed ID: 20362079
[TBL] [Abstract][Full Text] [Related]
58. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
[TBL] [Abstract][Full Text] [Related]
59. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
[TBL] [Abstract][Full Text] [Related]
60. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
Min LJ; Mogi M; Shudou M; Jing F; Tsukuda K; Ohshima K; Iwanami J; Horiuchi M
Hypertension; 2012 May; 59(5):1079-88. PubMed ID: 22454480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
